기사

[Edaily, Reporter Lee Jung-hoon] Prodizen Co., Ltd., a biotechnology company specializing in cell therapy, announced on the 27th that it had signed a strategic memorandum of understanding (MOU) with Honesty Plastic Surgery Clinic. Under the agreement, the two organizations will jointly pursue clinical research and product development in aesthetic dermatology.

Prodizen CEO Shim Soo-ja (right) poses with Dr. Jung Dong-woo, Medical Director of Honesty Plastic Surgery Clinic, following the MOU signing. (Photo courtesy of Prodizen)

The agreement aims to combine Prodizen’s biotechnology research and development infrastructure with the clinical experience Honesty Plastic Surgery Clinic has accumulated in medical practice. The clinic will be designated as Prodizen’s “Official Clinical Partner,” and the two organizations plan to establish a framework for cooperation spanning clinical consultation at the early stages of new product planning, academic research, and exchanges at international scientific conferences.

Key areas of cooperation include joint research in dermatology and anti-aging, with findings to be published in Korean and international academic journals; joint participation in major scientific conferences in Korea and abroad to present clinical research findings; and the planning of tailored products and improvements in ease of use based on feedback from clinical practice. Prodizen will provide the technical data and R&D resources needed for product development, while Honesty Plastic Surgery Clinic will contribute procedural expertise and professional insights from its medical staff to help develop medical devices and aesthetic dermatology solutions.

Dr. Jung, who serves as Prodizen’s Key Doctor, will lead clinical consultation and research under the partnership. He will advise on incorporating unmet needs from clinical practice into the R&D process and lead related clinical studies.

The two organizations will also pursue international academic exchanges based on their research findings. They plan to hold regular conference presentations and research exchange seminars in Korea and abroad, while expanding a multidisciplinary research network that enables physicians across various specialties to share clinical insights.

“Feedback from those who work directly with patients is the most important compass for developing innovative products,” said Shim Soo-ja, CEO of Prodizen. “Through our close partnership with Honesty Plastic Surgery Clinic, which brings extensive expertise and clinical know-how, we will develop high-quality solutions trusted by medical professionals and build a sustainable medical research ecosystem.”

“It is meaningful to have the opportunity to systematically translate our clinical experience into scientific knowledge alongside Prodizen, a company with proprietary expertise in cell therapy,” said Dr. Jung Dong-woo, Medical Director of Honesty Plastic Surgery Clinic. “We will contribute to the development of products that improve treatment outcomes and procedural convenience, and do our utmost to share our academic research findings in Korea and internationally.”

Prodizen is a biotechnology company operating in cell therapy and regenerative medicine. It supplies therapeutics and medical devices through its R&D capabilities and network of medical institutions. Led by Dr. Jung Dong-woo, Honesty Plastic Surgery Clinic specializes in aesthetic medicine and plastic surgery, providing personalized patient care while conducting research and academic activities.